| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/16/2013 | EP2544719A1 Cd37-binding molecules and immunoconjugates thereof |
| 01/16/2013 | EP2544718A1 Vaccines for pandemic influenza |
| 01/16/2013 | EP2544717A1 Method for protecting against disease caused by secondary pathogens |
| 01/16/2013 | EP2544716A2 Foot and mouth disease virus recombinant vaccines and uses thereof |
| 01/16/2013 | EP2544715A2 Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease |
| 01/16/2013 | EP2544714A1 Vaccine composition |
| 01/16/2013 | EP2544713A1 Immunogenic composition |
| 01/16/2013 | EP2544712A1 Immunogenic composition |
| 01/16/2013 | EP2544711A1 Treatment of streptococcal infections |
| 01/16/2013 | EP2544710A1 Immunogenic composition comprising s. pneumoniae polysaccharides conjugated to carrier proteins |
| 01/16/2013 | EP2544709A1 Methods for preventing and treating staphylococcus aureus colonization, infection and disease |
| 01/16/2013 | EP2544708A2 Conjugation process of bacterial polysaccharides to carrier proteins |
| 01/16/2013 | EP2544707A1 Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening |
| 01/16/2013 | EP2544694A2 A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| 01/16/2013 | EP2544693A1 A novel mucosal vaccination approach for herpes simplex virus type-2 |
| 01/16/2013 | EP2544688A2 Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| 01/16/2013 | EP2544680A2 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| 01/16/2013 | EP2190473B1 Peptide with reduced dimer formation |
| 01/16/2013 | CN1723039B Use for nerve growth factor antagonist in preparing medicine for treating post-surgical pain |
| 01/16/2013 | CN102884194A Methods and compositions containing Fc fusiong proteins for enhancing immune responses |
| 01/16/2013 | CN102884193A Novel pneumovirus compositions and methods for using the same |
| 01/16/2013 | CN102884085A Anti-ERBB3 antibodies |
| 01/16/2013 | CN102884084A 抗her2抗体及组合物 Anti-her2 antibody and compositions |
| 01/16/2013 | CN102884083A Nist DR5 binding polypeptides |
| 01/16/2013 | CN102884082A Neutralizing prolactin receptor antibodies and their therapeutic use |
| 01/16/2013 | CN102884081A Methods of treating autoimmune diseases with DLL4 antagonists |
| 01/16/2013 | CN102884079A Compositions and methods for treating hepatitis virus infection |
| 01/16/2013 | CN102884078A Expression of monoclonal antibodies in ciliate host cells |
| 01/16/2013 | CN102884006A Extracorporeal devices and methods of treating complications of pregnancy |
| 01/16/2013 | CN102883748A Methods for the treatment of IL-1beta related conditions |
| 01/16/2013 | CN102883747A Novel antibody to a carbonic anhydrase |
| 01/16/2013 | CN102883746A Cancer treatment |
| 01/16/2013 | CN102883745A Conjugation process |
| 01/16/2013 | CN102883744A Treatment or prevention of infection |
| 01/16/2013 | CN102876707A Preparation method of recombinant poliovirus I-type virus-like particles |
| 01/16/2013 | CN102876688A Method for preparing recombinant polio I virus-like particles |
| 01/16/2013 | CN102876682A Schistosoma Japonicum polymorphism antigen gene and application thereof as vaccine |
| 01/16/2013 | CN102876638A Recombinant influenza virus capable of realizing high-efficiency expression of HA protein, and preparation method and application of recombinant influenza virus |
| 01/16/2013 | CN102876620A Nontoxic ST28 streptococcus suis and application thereof |
| 01/16/2013 | CN102875685A Chimeric antigen receptor hFVIIL-CD8-OX40-CD3zeta and application thereof |
| 01/16/2013 | CN102875681A Anti-alpha v beta 6 antibodies and uses thereof |
| 01/16/2013 | CN102875680A Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| 01/16/2013 | CN102875679A Anti-platelet membrane glycoprotein vi monoclonal antibody |
| 01/16/2013 | CN102875678A Human anti-human CD20 monoclonal antibody molecule and application thereof |
| 01/16/2013 | CN102875677A Humanized anti-egfl7 antibodies and methods using same |
| 01/16/2013 | CN102875676A Human anti-human VEGF monoclonal antibody molecule and application thereof |
| 01/16/2013 | CN102875674A Anti-tetanotoxin antibody, and preparation method and application thereof |
| 01/16/2013 | CN102875657A Method for preparing telomerase polypeptide vaccine |
| 01/16/2013 | CN102872460A Refined egg yolk antibody compound for preventing and treating duck reovirus diseases and method for preparing refined egg yolk antibody compound |
| 01/16/2013 | CN102872459A Cell factor IL-16 and application of PepT1 expression regulated and controlled by cell factor IL-16 |
| 01/16/2013 | CN102872458A Therapeutic vaccine adjuvant |
| 01/16/2013 | CN102872457A Treatment of prdc in pigs |
| 01/16/2013 | CN102872456A One dose vaccination with mycoplasma hyopneumoniae |
| 01/16/2013 | CN102234645B Artificially synthesized promoter for gene therapy and vaccine development |
| 01/16/2013 | CN102154218B Hybridoma cell strain 4e9 and monoclonal antibody produced by using hybridoma cell strain 4e9 |
| 01/16/2013 | CN102133400B Method for removing split agent in vaccine preparation process |
| 01/16/2013 | CN102133399B Novel process for preparing influenza virus split vaccine |
| 01/16/2013 | CN102086447B Duck virus hepatitis strains and inactivated vaccine |
| 01/16/2013 | CN101456905B Bacteria 5 type secretory protein and construction method and application thereof |
| 01/16/2013 | CN101411876B Neurotoxic oligomers |
| 01/16/2013 | CN101401935B Astragalus polysaccharide adjuvant and uses in type I riemerella anatipestifer inactivated vaccine |
| 01/16/2013 | CN101294164B Expression of recombinant human metaphase factor (rh-Midkine), preparation and application of monoclone antibody |
| 01/16/2013 | CN101095053B Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 |
| 01/16/2013 | CN101024845B Use of nucleotide sequence for encoding protein of gag and pol, method for producing replication-defective retrovirus |
| 01/15/2013 | US8354522 Immunostimulatory oligoribonucleotides |
| 01/15/2013 | US8354507 humanized monoclonal antibodies; complementarity determining region of murine monoclonal antibody heavy chain variable domain operably fused to human heavy chain framework domain; induce apoptosis in HLA-DR-expressing tumor cells |
| 01/15/2013 | US8354247 Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| 01/15/2013 | US8354240 VMP-like sequences of pathogenic Borrelia |
| 01/15/2013 | US8354238 Method of immunoassaying specimen using aggregation reaction of microparticles and assay kit |
| 01/15/2013 | US8354115 Binding proteins; vaccines; increased cytokine and antibody production |
| 01/15/2013 | US8354114 Multi plasmid system for the production of influenza virus |
| 01/15/2013 | US8354113 Gene expressing a bifidobacterium surface-presented fusion protein |
| 01/15/2013 | US8354112 Glucose dehydrogenase/cytochrome fusion protein |
| 01/15/2013 | US8354111 Stable cell binding chimeric peptides |
| 01/15/2013 | US8354110 Compositions and methods for the prevention and treatment of autoimmune conditions |
| 01/15/2013 | US8354109 Multimeric Fc receptor polypeptides |
| 01/15/2013 | US8354108 Fully human antibody to human TNFα, molecular evolution and use thereof |
| 01/15/2013 | US8354107 Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
| 01/15/2013 | US8354106 Antibodies against HMGB1 and fragments thereof |
| 01/15/2013 | US8354105 Methods for modulating mannose content of recombinant proteins |
| 01/15/2013 | US8354104 Monoclonal antibodies for treatment of cancer |
| 01/15/2013 | US8354103 Human antibodies to human angiopoietin-like protein 4 |
| 01/15/2013 | US8354102 Antibodies directed to mGluR7 |
| 01/15/2013 | CA2687632C Lyophilised antigen composition |
| 01/15/2013 | CA2592136C Molecular sieve ssz-70 composition of matter and synthesis thereof |
| 01/15/2013 | CA2550583C Modified cea /b7 vector |
| 01/15/2013 | CA2466156C Ehrlichia disulfide bond formation proteins and uses thereof |
| 01/15/2013 | CA2461710C Incapacitated whole-cell immunogenic bacterial compositions |
| 01/15/2013 | CA2451864C Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| 01/15/2013 | CA2443323C Nucleic acid vaccines for prevention of flavivirus infection |
| 01/15/2013 | CA2400842C Novel compounds |
| 01/15/2013 | CA2323011C Method for the development of an hiv vaccine |
| 01/10/2013 | WO2013006842A2 Immunogenic compositions and uses thereof |
| 01/10/2013 | WO2013006838A1 Immunogenic combination compositions and uses thereof |
| 01/10/2013 | WO2013006837A1 Cationic oil-in-water emulsions |
| 01/10/2013 | WO2013006834A1 Oil-in-water emulsions that contain nucleic acids |
| 01/10/2013 | WO2013006825A1 Liposomes having useful n:p ratio for delivery of rna molecules |
| 01/10/2013 | WO2013006815A1 Methods and compositions to modulate antiviral and immune activity responses |
| 01/10/2013 | WO2013006797A1 Human respiratory syncytial virus vaccine |
| 01/10/2013 | WO2013006727A1 Modulation of tim receptor activity as cytoreductive therapy |